https://orcid.org/0000-0003-1883-2000
Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Hamid Reza Baradaran, Hojat Dehghanbanadaki, Farhad Moradpour, Babak Eshrati, Ghobad Moradi, Mobin Azami, Abdolkarim Haji Ghadery, Mohammad-Mehdi Mehrabi Nejad & Yousef Moradi. (2022) The effect of COVID-19 mRNA vaccines against postvaccination laboratory-confirmed SARS-CoV-2 infection, symptomatic COVID-19 infection, hospitalization, and mortality rate: a systematic review and meta-analysis. Expert Review of Vaccines 21:10, pages 1455-1464.
Read now
Read now
Articles from other publishers (19)
Haruhisa Fukuda, Megumi Maeda & Fumiko Murata. (2023) Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study. Vaccine.
Crossref
Crossref
Jun Zhang, Wenxing Yang, Feijun Huang & Kui Zhang. (2023) Effectiveness of mRNA and viral‐vector vaccines in epidemic period led by different SARS‐CoV‐2 variants: A systematic review and meta‐analysis. Journal of Medical Virology 95:3.
Crossref
Crossref
Takuma Tsuzuki Wada, Kazuhiro Yokota, Sakon Sakai, Machika Soma, Hiroshi Kajiyama, Norihito Tarumoto, Shigefumi Maesaki, Takuya Maeda, Makoto Nagata & Toshihide Mimura. (2023) Evaluation of anti-severe acute respiratory syndrome coronavirus 2 antibody levels in coronavirus disease breakthrough infection during immunosuppressive therapy in a patient with connective tissue disease-related interstitial lung disease. Modern Rheumatology Case Reports 7:1, pages 288-292.
Crossref
Crossref
Siguna MuellerSiguna Mueller. 2023. Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2. Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2
131
162
.
Harapan Harapan, Malik Sallam, Raisha Fathima, Hendrix Indra Kusuma, Samsul Anwar, Widhy Yudistira Nalapraya, Adityo Wibowo, Ketut Dewi Kumara Wati, Ayunda Medina, Anna Hanifa Defrita, Yesi Astri, Arie Prasetyowati, Nurfarahin Nurfarahin, Afriyani Khusna, Setya Oktariana, Sarifuddin Anwar, Milza Oka Yussar, Siti Khotimah, Bahagia Willibrordus Maria Nainggolan, Putri Rizki Amalia Badri, Raden Argarini, Wira Winardi, Khan Sharun, Rosaria Indah, Yogambigai Rajamoorthy, Abram L. Wagner & Mudatsir Mudatsir. (2022) Willingness to Pay (WTP) for COVID-19 Vaccine Booster Dose and Its Determinants in Indonesia. Infectious Disease Reports 14:6, pages 1017-1032.
Crossref
Crossref
Micaela Garziano, Olga Utyro, Sergio Strizzi, Claudia Vanetti, Irma Saulle, Chiara Conforti, Federica Cicilano, Francesco Ardizzone, Gioia Cappelletti, Mario Clerici, Fiona Limanaqi & Mara Biasin. (2022) Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose. International Journal of Molecular Sciences 23:22, pages 14341.
Crossref
Crossref
Rodrigo A. V. Browne, Ludmila L. P. Cabral, Gledson T. A. Oliveira, Geovani A. D. Macêdo, Júlio Sócrates, Raíssa de M. Silva, Maria B. F. Araújo, Yuri A. Freire & Eduardo C. Costa. (2022) Life-Space Mobility and Objectively Measured Movement Behavior in Older Adults with Hypertension after Receiving COVID-19 Vaccination. International Journal of Environmental Research and Public Health 19:19, pages 12532.
Crossref
Crossref
Alisan Kayabolen, Ugur Akcan, Doğancan Özturan, Hivda Ulbegi‐Polat, Gizem Nur Sahin, Nareg Pinarbasi‐Degirmenci, Canan Bayraktar, Gizem Soyler, Ehsan Sarayloo, Elif Nurtop, Berna Ozer, Gulen Guney‐Esken, Tayfun Barlas, Ismail Selim Yildirim, Ozlem Dogan, Sercin Karahuseyinoglu, Nathan A. Lack, Mehmet Kaya, Cem Albayrak, Fusun Can, Ihsan Solaroglu & Tugba Bagci‐Onder. (2022) Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In Vivo. Advanced Science 9:27, pages 2201294.
Crossref
Crossref
Kazem Rahmani, Rasoul Shavaleh, Mahtab Forouhi, Hamideh Feiz Disfani, Mostafa Kamandi, Rozita Khatamian Oskooi, Molood Foogerdi, Moslem Soltani, Maryam Rahchamani, Mohammad Mohaddespour & Mostafa Dianatinasab. (2022) The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Frontiers in Public Health 10.
Crossref
Crossref
David W. McCormick, Stacey L. Konkle, Reed Magleby, Ayan K. Chakrabarti, Blake Cherney, Kristine Lindell, Apophia Namageyo-Funa, Susanna Visser, Raymond A. Soto, Marisa A.P. Donnelly, Ginger Stringer, Brett Austin, Mark E. Beatty, Sarah Stous, Bernadette A. Albanese, Victoria T. Chu, Meagan Chuey, Elizabeth A. Dietrich, Jan Drobeniuc, Jennifer M. Folster, Marie E. Killerby, Jennifer A. Lehman, Eric C. McDonald, Jasmine Ruffin, Noah G. Schwartz, Sarah W. Sheldon, Sadia Sleweon, Natalie J. Thornburg, Laura J. Hughes, Marla Petway, Suxiang Tong, Melissa J. Whaley, Hannah L. Kirking, Jacqueline E. Tate, Christopher H. Hsu & Almea Matanock. (2022) SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge – Denver, Colorado, and San Diego, California, January–April 2021. Vaccine 40:33, pages 4845-4855.
Crossref
Crossref
Kim Bouillon, Bérangère Baricault, Jérémie Botton, Marie-Joëlle Jabagi, Marion Bertrand, Laura Semenzato, Stéphane Le Vu, Jérôme Drouin, Rosemary Dray-Spira, Alain Weill & Mahmoud Zureik. (2022) Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. BMJ Medicine 1:1, pages e000104.
Crossref
Crossref
Melissa M Higdon, Brian Wahl, Carli B Jones, Joseph G Rosen, Shaun A Truelove, Anurima Baidya, Anjalika A Nande, Parisa A ShamaeiZadeh, Karoline K Walter, Daniel R Feikin, Minal K Patel, Maria Deloria Knoll & Alison L Hill. (2022) A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infectious Diseases 9:6.
Crossref
Crossref
Wing Ying Au & Peter Pak-Hang Cheung. (2022) Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ, pages e069989.
Crossref
Crossref
Jonas Björk, Carl Bonander, Mahnaz Moghaddassi, Magnus Rasmussen, Ulf Malmqvist, Malin Inghammar & Fredrik Kahn. (2022) COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022. Eurosurveillance 27:18.
Crossref
Crossref
Sarah M. Hatcher, Stacy M. Endres-Dighe, Frederick J. Angulo, Amit Srivastava, Jennifer L. Nguyen, Farid Khan, Catherine Martin, David L. Swerdlow, John M. McLaughlin, Nneka Ubaka-Blackmore & Linda Morris Brown. (2022) COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January–30 June 2021). Vaccines 10:3, pages 393.
Crossref
Crossref
Fredrik Kahn, Carl Bonander, Mahnaz Moghaddassi, Magnus Rasmussen, Ulf Malmqvist, Malin Inghammar & Jonas Björk. (2022) Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022. Eurosurveillance 27:9.
Crossref
Crossref
Megan Young, Harry Crook, Janet Scott & Paul Edison. (2022) Covid-19: virology, variants, and vaccines. BMJ Medicine 1:1, pages e000040.
Crossref
Crossref
Alexander Suvorov, Tatiana Gupalova, Yulia Desheva, Tatiana Kramskaya, Elena Bormotova, Irina Koroleva, Olga Kopteva & Galina Leontieva. (2022) Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus. Frontiers in Pharmacology 12.
Crossref
Crossref
Alexander Suvorov, Tatiana Gupalova, Yulia Desheva, Tatiana Kramskaya, Elena Bormotova, Irina Koroleva, Olga Kopteva & Galina Leontieva. (2022) Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus. Frontiers in Pharmacology 12.
Crossref
Crossref